Peptide · Approved

Lixisenatide

A short-acting GLP-1 receptor agonist (Adlyxin) for type-2 diabetes.

Key facts

  • Also known as: Adlyxin
  • Status: Approved
  • Used for: Diabetes (GLP-1)
  • Natural counterpart: An exendin-4-based mimic of natural GLP-1.
  • Target enzyme / receptor: GLP-1 receptor (GLP-1R) — class B GPCR
  • Signalling pathway: Gαs → cAMP → PKA → insulin secretion
    In plain terms: Boosts meal-time insulin and slows stomach emptying.
  • Crystal / cryo-EM structure: Available  PDB 5VAI ↗

Status & safety

This is an approved medicine — prescription-only in most countries. Only use it under a licensed clinician, obtained through a pharmacy.

Research & clinical studies

Explore the biochemistry and clinical evidence for Lixisenatide — these open live, date-sorted searches, so they always show the latest.

Read research papers on PubMed ↗

Clinical studies (ClinicalTrials.gov) ↗ Google Scholar ↗ Related guide → All peptides & profiles →

Not medical advice. Chemdu is an educational resource and does not sell, prescribe or supply any peptide. Consult a licensed professional about any medicine or supplement.